IONS Q3 2025 Earnings — Ionis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

IONSIonis Pharmaceuticals, Inc.

$13B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$157M+17.1% YoY

Gross Profit

$154M98.5% margin

Operating Income

-$160M-102.2% margin

Net Income

-$129M-82.1% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

-65.3%

Cash Flow

Operating Cash Flow

-$131M

Free Cash Flow

-$135M

Stock-Based Comp.

$31M

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$2.4B

Stockholders' Equity

$618M

Cash & Equivalents

$338M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$157M	$134M	+17.1%
Gross Profit	$154M	$133M	+16.3%
Operating Income	-$160M	-$149M	-7.8%
Net Income	-$129M	-$140M	+8.5%

Revenue Segments

Commercial Member

$116M52%

Royalty

$76M34%

Product

$32M14%